Lupin

Intimation of Closure of Trading Window

25 Mar, 2026 | 03:50pm • Source: BSE

Lupin Limited has informed the Exchange regarding a press release dated March 25, 2026, titled "Lupin Receives Tentative Approval from U.S. FDA for Pitolisant Tablets

25 Mar, 2026 | 11:34am • Source: NSE

Lupin Receives Tentative Approval from U.S. FDA for Pitolisant Tablets

25 Mar, 2026 | 09:12am • Source: BSE

Intimation regarding allotment of 135892 equity shares under ESOP.

24 Mar, 2026 | 12:44pm • Source: BSE

Lupin Limited has informed the Exchange regarding a press release dated March 19, 2026, titled "Lupin Manufacturing Solutions Announces Expansion of Manufacturing Facility at Dabhasa,...

19 Mar, 2026 | 10:46am • Source: NSE

Lupin Manufacturing Solutions Announces Expansion of Manufacturing Facility at Dabhasa, India

19 Mar, 2026 | 08:13am • Source: BSE

Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

02 Mar, 2026 | 09:02pm • Source: BSE

Receipt of Establishment Inspection Report (EIR) by the Company form the U.S. FDA for its facility in Goa, India.

27 Feb, 2026 | 01:03pm • Source: BSE

Vinita Gupta, Lupin CEO, Named to the 2026 CNBC Changemakers List of Women Transforming Business for making Medicines Accessible and Affordable for Americans.

26 Feb, 2026 | 08:38pm • Source: BSE

Vinita Gupta, Lupin CEO, Named to the 2026 CNBC Changemakers List of Women Transforming Business for Making Medicines Accessible and Affordable for Americans.

26 Feb, 2026 | 08:02pm • Source: BSE

Lupin Ranks No. 1 Globally in Pharma; Tops All Sectors in India in S&P ESG Assessment 2025.

26 Feb, 2026 | 04:36pm • Source: BSE

Lupin Announces the Approval and Launch of Brivaracetam Oral Solution in the United States.

24 Feb, 2026 | 07:11pm • Source: BSE

Lupin Receives European Commission Approval for Biosimilar Ranibizumab

23 Feb, 2026 | 03:30pm • Source: BSE

Lupin Signs License and Supply Agreement with Spektus to Commercialize Novel Antidepressant DeslaFlex in Canada.

16 Feb, 2026 | 04:00pm • Source: BSE

Intimation of allotment of 75273 equity shares under ESOP.

13 Feb, 2026 | 04:21pm • Source: BSE

Intimation about participating in the Analyst/Institutional Investors Meet.

10 Feb, 2026 | 05:12pm • Source: BSE

Settlement and License Agreement

10 Feb, 2026 | 07:44am • Source: BSE

Made in India- The story of Desh Bandhu Gupta, Lupin and Indian Pharma Book Launched in Mumbai

09 Feb, 2026 | 11:01am • Source: BSE

Lupin Launches Dasatinib Tablets in the United States.

02 Feb, 2026 | 11:14am • Source: BSE

Lupin and TB Alliance Join Forces to Advance Telacebec for the Treatment of Tuberculosis and Other Mycobacterial Diseases.

02 Feb, 2026 | 10:11am • Source: BSE